Utilizing these FA-linked Pt (IV) prodrugs, it was demonstrated that increased CD36 expression in cisplatin-resistant ovarian cancer cells could be leveraged to overcome cisplatin resistance [74]. This evidence concerns the gene CD36 and ovarian carcinoma.